29 Jan 2019 07:00
January 29, 2019
Verseon Corporation
("Verseon" or the "Company")
Directorate change
Fremont, Calif.—Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company, announces that Xavier Rolet, on account of his recent executive appointment, will be stepping down from his role as a non-executive director on February 23, 2019 in order to avoid any potential conflicts with Verseon and its subsidiaries' businesses.
"We thank Xavier for his contribution and wish him every success in his new role," said Adityo Prakash, CEO of Verseon.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform paired with a comprehensive in-house chemistry and biology workflow to build a growing drug development pipeline. Through its wholly owned subsidiary BlockRules Ltd., Verseon is also pioneering blockchain technology for regulated securities.
-Ends-
For further information, please contact
Verseon Corporation | www.verseon.com |
Sebastian Wykeham / Tina Schlafly | +1 (510) 225 9000 |
|
|
Arden Partners (NOMAD and Joint Broker) |
|
Ruari McGirr / Ciaran Walsh | +44 (0) 20 7614 5900 |
|
|
Cantor Fitzgerald Europe (Joint Broker) |
|
Phil Davies | +44 (0) 20 7894 7000 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) |
|
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts |
|
Simon Vane Percy | +44 (0) 1737 821 890 |
VERS.L (VERS)